Diabetes Self-Management Blog

Editor’s Note: This is the tenth post in our miniseries about diabetes drugs. Tune in on October 16 for the next installment.

This class of drugs, also known as the nonsulfonylurea secretagogues, is relatively new compared to the sulfonylureas (chlorpropamide [brand name Diabinese], glyburide [DiaBeta, Glynase, Micronase], glipizide [Glucotrol], glipizide extended-release [Glucotrol XL], and glimepiride [Amaryl]), with the first meglitinide being approved by the U.S. Food and Drug Administration in 1997.

Meglitinides act in a similar manner to the sulfonylureas but with a few major differences. For example, meglitinides bind to the sulfonylurea receptor in beta cells (the insulin-producing cells of the pancreas), but at a different part of the receptor than the sulfonylureas do. The interaction of the meglitinides with the receptor is not as “tight” as that of the sulfonylureas, translating to a much shorter duration of action and a higher blood glucose level needed before the drugs produce insulin secretion from the pancreas.

There are currently two meglitinides available in the United States — repaglinide (Prandin) and nateglinide (Starlix). Both are approved for use alone and in combination with other oral diabetes drugs in people with Type 2 diabetes. The major effect of meglitinides is the reduction of after-meal blood glucose levels, which results in a reduction in HbA1c (an indicator of blood glucose control over the previous 2–3 months).

Repaglinide has been shown to be roughly as effective as the sulfonylureas at reducing HbA1c levels, causing a decrease of roughly 1.5% to 2%. Nateglinide reduces HbA1c levels by approximately 0.6% to 1.2%, but it causes fewer instances of hypoglycemia (low blood glucose) than repaglinide. Since these drugs stimulate the body’s own release of insulin, they tend to lose effectiveness over time as a person’s diabetes progresses.

In a head to head study between repaglinide and nateglinide, repaglinide used alone produced a better reduction in HbA1c and fasting plasma glucose levels than nateglinide. However, reductions in HbA1c are greatest when either of these drugs is given in combination with metformin (Glucophage and others), a thiazolidinedione (Actos, Avandia) or an alpha-glucosidase inhibitor (Precose, Glyset).

Both of these drugs have relatively short half-lives (meaning they disappear from the body fairly quickly) and must be taken roughly 1–30 minutes before each meal. The recommended starting dose for nateglinide is 120 milligrams taken three times a day prior to meals, with a lower dose of 60 milligrams taken three times a day recommended for people who are close to their HbA1c goal. The starting dose for repaglinide for people who have not previously taken glucose-lowering medicines or for those with an HbA1c level below 8.0% is 0.5 milligrams usually taken three times a day prior to meals; for all others, the recommended starting dose is 1–2 milligrams usually taken three times a day before meals.

Repaglinide interacts with certain other drugs — particularly gemfibrozil (Lopid; a cholesterol-lowering medicine) and the combination of gemfibrozil and itraconazole (the antifungal Sporanox), which raise the blood levels of repaglinide roughly 28-fold and 72-fold, respectively. Dose adjustments of repaglinide are necessary in people with severe kidney dysfunction and moderate to severe liver dysfunction. Drug interactions are less likely with nateglinide, but this medicine should be used with caution by people who have liver dysfunction. As noted above, repaglinide is more likely to cause hypoglycemia than nateglinide, and repaglinide also causes weight gain to a greater extent than nateglinide (which has been shown to have no effect on weight in some studies).

Click here for other installments of “Diabetes Drugs.”

POST A COMMENT       
  

Comments
  1. I didn’t find one of my drug listed.I take two, one being Metformin, and the unlisted one is glipizide XL, 2.5MG What can you tell me about this drug. Thanks

    Posted by Carolyn Wright |
  2. Hello Ms. Wright,

    Thanks for your comment. You can learn more about glipizide in the blog entry “Diabetes Drugs: Sulfonylureas.”

    Thank you for your interest in Diabetes Self-Management.

    Sincerely,
    Diane Fennell
    Web Editor

    Posted by Diane Fennell |
  3. I take Starlix; but I keep forgetting to take it before each meal. Usually, I easily remember to take it before breakfast. The other meals are about 50/50. Sometimes I remember it between a meal or after a meal. Any suggestions? Thanks.

    Posted by Barbara Kyle |

Post a Comment

Note: All comments are moderated and there may be a delay in the publication of your comment. Please be on-topic and appropriate. Do not disclose personal information. Be respectful of other posters. Only post information that is correct and true to your knowledge. When referencing information that is not based on personal experience, please provide links to your sources. All commenters are considered to be nonmedical professionals unless explicitly stated otherwise. Promotion of your own or someone else's business or competing site is not allowed: Sharing links to sites that are relevant to the topic at hand is permitted, but advertising is not. Once submitted, comments cannot be modified or deleted by their authors. Comments that don't follow the guidelines above may be deleted without warning. Such actions are at the sole discretion of DiabetesSelfManagement.com. Comments are moderated Monday through Friday by the editors of DiabetesSelfManagement.com. The moderators are employees of R.A. Rapaport Publishing, Inc., and do not report any conflicts of interest. A privacy policy setting forth our policies regarding the collection, use, and disclosure of certain information relating to you and your use of this Web site can be found here. For more information, please read our Terms and Conditions.


Oral Medicines
FDA Panel Votes in Favor of Inhalable Insulin; Diet Drug Recalled (04/09/14)
Many Americans Taking Meds That Work Against Each Other (03/14/14)
New Type 2 Diabetes Drug Approved (01/10/14)
Metformin Affects Hearts of Men and Women Differently (01/03/14)

 

 

Disclaimer of Medical Advice: You understand that the blog posts and comments to such blog posts (whether posted by us, our agents or bloggers, or by users) do not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs. The opinions and other information contained in the blog posts and comments do not reflect the opinions or positions of the Site Proprietor.


Carbohydrate Restriction: An Option for Diabetes Management
Some people find that decreasing the amount of carbohydrate they eat can help with blood glucose control. Here’s what to know about this approach.

Insulin Patch Pumps: A New Tool for Type 2
Patch pumps are simpler to operate than traditional insulin pumps and may be a good option for some people with Type 2 diabetes who need insulin.

How Much Do You Know About Vitamins?
Learn what these micronutrients can and can’t do for you.

Complete table of contents
Get a FREE ISSUE
Subscription questions